BrainsWay’s SWIFT Deep TMS Protocol Cuts Treatment Time by 70%, Maintaining Efficacy
Event summary
- BrainsWay’s SWIFT Deep TMS protocol achieved 87.8% response rate and 78.0% remission rate in a randomized non-inferiority trial.
- The accelerated protocol reduces the traditional 20-visit acute treatment phase to just 6 half days.
- Median time to remission was 21 days for SWIFT versus 28 days for the standard protocol.
- Evernorth® Behavioral Health eliminated prior authorization requirements for Deep TMS.
- The study incorporated input from both patients and providers in urban and rural areas.
The big picture
BrainsWay’s SWIFT protocol addresses a critical logistical barrier in interventional psychiatry, aligning with the rising demand for non-drug depression therapies. The accelerated treatment model could redefine how mental health services are delivered, particularly as payers reduce administrative hurdles. This innovation positions BrainsWay to capture a larger share of the $333 billion annual economic burden of Major Depressive Disorder in the U.S.
What we're watching
- Adoption Dynamics
- How the 70% reduction in clinic visits will affect patient retention and market penetration.
- Regulatory Tailwinds
- Whether Evernorth’s elimination of prior authorization will accelerate payer adoption.
- Competitive Positioning
- The pace at which BrainsWay can scale SWIFT to maintain leadership in non-invasive depression treatments.
Related topics